GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Lab] CPC orfo — Janoshik came back 98.3% against a claimed 97.5% — 31 comments in the full submission. View in context.
968
c/orforglipron·submitted 7 months ago by u/maren_sorensen

[Lab] CPC orfo — Janoshik came back 98.3% against a claimed 97.5%

Questionbranch of 6 comments

CPC orfo — Janoshik came back 98.3% against a claimed 97.5%. That is the headline. The document, the batch and the service are below so you can argue with the method rather than with me. Pulling the figures out of the title: 98.3% and 97.5%. All of it is written down as it happened rather than reconstructed. Assumed…

Read the full submission and all 31 comments →

This branch

6 comments, started 7 months ago
u/hsa_math13 points·7 months ago·edited

Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.

replysharereportpermalink
u/whois_wanda3 points·7 months ago

oral and non-peptide is the whole engineering story

replysharereportpermalink
u/canada_coverage2 points·7 months ago

Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.

replysharereportpermalink
u/chidi_yilmaz1 point·7 months ago

Careful — purity methods for peptides do not read across to a small molecule and the numbers are not equivalent.

replysharereportpermalink
u/maren_sorensenOP9 points·7 months ago

Daily dosing, so what does the exposure profile look like across the day?

replysharereportpermalink
u/zeynep_ndiaye-21 points·7 months ago

Daily rather than weekly sounds trivial until you think about what a missed dose means in each case.

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/orforglipron
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/phase_two_peteu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →